🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 55405U108 (prev. 576818108 )
- Market Cap
- Micro Cap · $2 Million
- Previous Symbol
- MZT (changed 12/18/2007)
- Previous Name
- Matritech, Inc.
Business: Matritech is using its patented proteomics technology to develop highly specific diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22(R) Test Kit and NMP22(R) BladderChek(TM) test, have been approved for the monitoring and diagnosis of bladder cancer. NMP22 BladderChek test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, exclusively licensed from the Massachusetts Institute of Technology, which correlates levels of NMPs in body fluids to the presence of cancer. The Company has discovered other proteins associated with cervical, prostate, breast and colon cancer and has plans to develop additional diagnostics for each of those cancers.
Notes: January 18, 2008 MZT Holdings, Inc., formerly known as Matritech, Inc. announced today that it has filed a Certificate of Dissolution with the Secretary of the State of Delaware, which filing was effective today. In connection with this filing, effective as of the close of business today, MZT Holdings closed its stock transfer books and discontinued recording transfers of shares of its common stock, except for transfers by will, intestate succession or operation of law.
Company Contact
- CEO
- Stephen D. Chubb
- CFO
- Richard A. Sandberg
- COO
- David L. Corbet
- Headquarters
- 330 Nevada Street, Newton, MA 02460
- Phone
- 617-928-0820
- Fax
- 617-928-0821
- Investor Relations
- Kathleen O'Donnell · 617-512-4519